Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
NSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.07 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)51.99K
Market Cap
$76.59M
Enterprise Value$65.84M
Total Cash (Recent Filing)$26.09M
Total Debt (Recent Filing)$1.64M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Aug 12, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding30,635,345
10 Day Avg. Volume44,413
30 Day Avg. Volume51,993
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.70
Price to Sales (P/S)0.00
P/FCF Ratio-2.82
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue2.40
Enterprise Value/Gross Profit43.72
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$4.50Price Target Upside80.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
InspireMD News
PremiumCompany Announcements
InspireMD Holds Annual Stockholders Meeting and Elections
PremiumCompany Announcements
InspireMD Appoints New CFO Amidst Strategic Expansion
PremiumCompany Announcements
InspireMD Inc. Reports Q1 2025 Financial Results
PremiumCompany Announcements
InspireMD Inc’s Earnings Call: Growth Amid Challenges
PremiumPre-Earnings
Is NSPR a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.
Analyst RecommendationAnalyst recommends a Buy rating and a $5 price target.
Business GrowthInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Market ShareBest-in-class data should result in fast share taking for InspireMD's CGuard.
Product PerformanceThe 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.
Regulatory ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Bears Say
Options Prices
Currently, No data available
---
Ownership Overview
24.99% Insiders
0.06% Mutual Funds
31.58% Other Institutional Investors
43.37% Public Companies and
Individual Investors
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $2.07 and its highest was $3.80 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $76.59M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 12, 2025 which is in 63 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 09, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.02.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.26.
How many shares outstanding does InspireMD have?
InspireMD has 30,635,345 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (80.00% Upside)
$4.50 (80.00% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.06%
12-Months-Change
Fundamentals
Return on Equity
-113.95%
Trailing 12-Months
Asset Growth
-7.99%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
NSPR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments and challenges. While there was growth in CGuard revenue and significant progress in clinical trials and commercial preparations, the company faced increased operating expenses and a higher net loss. The anticipated delay in FDA approval also presents a challenge. However, the potential U.S. market opportunity and strategic progress provide optimism.Read More>NSPR Stock 12 Month Forecast
Average Price Target
$4.50
▲(80.00%Upside)